Novel Therapeutics for Pandemic and Epidemic Flu

大流行性流感和流行性流感的新疗法

• 批准号: 6789170
• 负责人: Fang Fang
• 金额: $ 50万
• 依托单位: NEXBIO, INC.
• 依托单位国家: 美国
• 财政年份: 2004
• 资助国家: 美国
• 起止时间: 2004-09-15 至 2006-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6789170
• 关键词: antiviral agents; cell line; chimeric proteins; communicable disease control; cytotoxicity; drug design /synthesis /production; influenza; intermolecular interaction; polymerase chain reaction; protease inhibitor; protein engineering; protein purification; recombinant proteins; serine proteinases; transfection /expression vector

DESCRIPTION (provided by applicant): Broad-spectrum therapeutics for influenza are critically needed to address the problem of influenza pandemics, a major threat to the public health globally. We have proposed studies that aim at generating a novel class of fusion proteins capable of blocking infections by all strains of influenza viruses. Specifically, the fusion protein is composed of a protease inhibitor that inhibits activation of all influenza viruses and an anchoring domain that helps to enrich the drug and prolong the drug retention on the respiratory epithelium. In the proposed phase I study, we will generate this proteinase inhibitor and its fusion proteins, compare their functional activities in vitro and choose the best construct for phase II study.

描述(申请人提供)：迫切需要广谱的流感疗法来解决流感大流行的问题，流感大流行是全球公共卫生的主要威胁。我们提出的研究旨在产生一种新型的融合蛋白，能够阻止所有流感病毒株的感染。具体地说，融合蛋白由抑制所有流感病毒激活的蛋白酶抑制剂和有助于丰富药物并延长药物在呼吸道上皮细胞上滞留的锚定结构域组成。在拟议的第一阶段研究中，我们将制备这种酶抑制剂及其融合蛋白，比较它们的体外功能活性，并选择最佳结构用于第二阶段研究。